CN111686070A - Water-soluble CBD (CBD-based) oil-soluble CBD gel - Google Patents
Water-soluble CBD (CBD-based) oil-soluble CBD gel Download PDFInfo
- Publication number
- CN111686070A CN111686070A CN202010671485.2A CN202010671485A CN111686070A CN 111686070 A CN111686070 A CN 111686070A CN 202010671485 A CN202010671485 A CN 202010671485A CN 111686070 A CN111686070 A CN 111686070A
- Authority
- CN
- China
- Prior art keywords
- cbd
- oil
- water
- soluble
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of gynecological gel, and discloses an oil-soluble CBD gel added with water-soluble CBD, which is characterized by comprising the following raw materials in parts by weight: water, humectant, emollient, solubilizer, rheology regulator, water soluble cannabidiol, EDTA-2Na, essence and antiseptic, and optionally oleum Cannabis, oleum Oenotherae Erythrosepalae, Cannabidiol (CBD) and adjuvants. According to the water-soluble CBD oil-soluble CBD gel, the CBD with high purity is embedded by the packaging material with good water solubility, so that the water solubility of the CBD is changed, the water solubility and the utilization rate of the CBD are greatly improved, the effective active additive cannabidiol has good antibacterial and anti-inflammatory effects, can be combined with or inserted into a cell membrane, changes the fluidity and other physiological properties of the membrane, can effectively inhibit the growth of thalli, can effectively relieve anxiety, and can play a role in metabolism and immunoregulation by regulating and controlling the level of inflammatory factors, controlling the generation of interferon and the like.
Description
Technical Field
The invention relates to the technical field of gynecological gel, in particular to oil-soluble CBD gel added with water-soluble CBD.
Background
The gynecological gel is a gynecological medicine, is a gel, is used for treating various gynecological vaginitis and cervicitis, including bacterial vaginitis, trichomonas vaginitis, mixed vaginitis, gonococcal infection and chronic cervicitis, can cause drug resistance of pathogenic bacteria and kill a large amount of beneficial bacteria by abuse or use of antibiotics, and destroys the balance of vaginal flora, thereby causing vigorous fungus growth, refractory and difficult winding of gynecological diseases and difficult thorough radical cure.
The gynecological gel has the effects of diminishing inflammation, sterilizing and relieving itching, and has an obvious inhibiting effect on the growth of pathogenic microorganisms such as staphylococcus aureus, escherichia coli, gonococcus, candida albicans, fungi, saccharomycetes and the like, but in the using process of the conventional gynecological gel, medicinal components do not fully enter a human body to diminish inflammation, so that repeated inflammation attacks can be caused, and the problem is solved by adding the water-soluble CBD oil-soluble CBD gel.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides the oil-soluble CBD gel with the addition of water-soluble CBD, which has the advantages of fully entering the human body to improve the drug effect, accelerating the treatment of inflammation and the like, and solves the problem that the inflammation is repeatedly caused because the drug ingredients do not fully enter the human body to perform anti-inflammation treatment on the inflammation in the use process of the existing gynecological gel.
(II) technical scheme
In order to achieve the purposes of fully entering human bodies, improving the drug effect and accelerating the treatment of inflammation, the invention provides the following technical scheme:
the water-soluble CBD oil-soluble CBD gel comprises the following raw materials in parts by weight: water, humectant, emollient, solubilizer, rheology regulator, water soluble cannabidiol, EDTA-2Na, essence and antiseptic, and optionally oleum Cannabis, oleum Oenotherae Erythrosepalae, Cannabidiol (CBD) and adjuvants.
Preferably, 66.2-89.4 parts of water, 8-18 parts of humectant, 2-8 parts of emollient, 0.1-1 part of solubilizer, 0.1-1 part of rheological regulator, 0.3-5 parts of water-soluble cannabidiol, 0.01-0.2 part of EDTA-2 Na0.05-0.5 part of essence and 0.1-0.3 part of preservative.
Preferably, the hemp seed oil accounts for 30-45 wt%, the evening primrose oil accounts for 20-50 wt%, and the Cannabidiol (CBD) accounts for 10-40 wt%.
Preferably, the auxiliary materials comprise 5-30 parts of glycerol, 5-50 parts of gelatin, 0.2-5 parts of fructose, 0.2-5 parts of sorbitol and 5-50 parts of purified water.
Preferably, the humectant comprises one or more of glycerin, propylene glycol, 1, 3-butanediol, glyceryl polyether-26, sodium hyaluronate, trehalose, allantoin, betaine and oat-beta-glucan.
Preferably, the emollient comprises one or more of petrolatum, mineral oil, coconut oil, sunflower oil, corn oil and rapeseed oil, soy myristate, octyl caprylate, oleyl oleate, hexyl laurate and isopropyl palmitate, ethoxylated glycerides, PEG-6 caprylic/capric triglycerides, PEG-60 corn oleyl mixed esters and PEG-7 olive oleate, lauryl alcohol, oleyl alcohol, octyl dodecanol and hexyl decanol, dioctyl cyclohexane.
Preferably, the solubilizer comprises one or more of PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil.
Preferably, the rheology modifier comprises one or more of xanthan gum, carbomer, hydroxyethyl cellulose, hydroxypropyl cellulose and acrylic acid polymers.
Preferably, the essence comprises essence permitted in cosmetic specifications, and the preservative is one or more of ethylparaben, sodium benzoate, benzalkonium chloride, dmdmdmh (dimethyloldimethylhydantoin) and diazolidinyl urea.
(III) advantageous effects
Compared with the prior art, the invention provides the oil-soluble CBD gel added with the water-soluble CBD, which has the following beneficial effects:
1. according to the water-soluble CBD oil-soluble CBD gel, the water-soluble cannabidiol is embedded with the CBD with high purity by the packing material with good water solubility on the premise that the molecular structure of the cannabidiol is not changed, so that the water solubility of the CBD is changed, the water solubility and the utilization rate of the CBD are greatly improved, the cannabidiol which is an effective active additive has good antibacterial and anti-inflammatory effects, inflammation caused by bacterial infection can be effectively removed, and the cannabidiol belongs to a natural plant extract, is safe and has no side effect.
2. According to the water-soluble CBD oil-soluble CBD gel, the cannabis sativa oil is rich in oleic acid, linoleic acid, alpha-linolenic acid, gamma-linoleic acid (GLA) and other human essential unsaturated fatty acids, the gamma-linoleic acid (GLA) can be combined with or inserted into a cell membrane after entering the cell wall, the fluidity and other physiological properties of the membrane are changed, and the thallus growth can be effectively inhibited.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
the water-soluble CBD oil-soluble CBD gel comprises the following raw materials in parts by weight: water, a humectant, an emollient, a solubilizer, a rheology regulator, water-soluble cannabidiol, EDTA-2Na, essence and a preservative, and also comprises hemp seed oil, evening primrose oil, Cannabidiol (CBD) and auxiliary materials, wherein 66.2 parts of water, 8 parts of humectant, 2 parts of emollient, 0.1 part of solubilizer, 0.1 part of rheology regulator, 0.3 part of water-soluble cannabidiol, 0.01 part of EDTA-2 Na0.05 part of essence, 0.1 part of preservative, the weight percentage of the hemp seed oil is 30 percent, the weight percentage of the evening primrose oil is 20 percent, the weight percentage of Cannabidiol (CBD) is 10 percent, the auxiliary materials comprise 5 parts of glycerol, 5 parts of gelatin, 0.2 part of fructose, 0.2 part of sorbitol and 5 parts of purified water, the humectant comprises one or a plurality of compositions of glycerol, propylene glycol, 1, 3-butanediol, glycerol polyether-26, sodium hyaluronate, trehalose, allantoin, betaine and oat-beta-glucan, the emollient comprises mineral ester, mineral oil, coconut oil, sunflower oil, corn oil and rapeseed oil, soybean myristate, octyl caprylate, oleyl oleate, hexyl laurate and isopropyl palmitate, ethoxylated glyceride, PEG-6 caprylic/capric triglyceride, PEG-60 corn oil mixed ester and PEG-7 olive oleate, one or more of lauryl alcohol, oleyl alcohol, octyl dodecanol and hexyl decanol, and dioctyl cyclohexane, the solubilizer comprises one or more of PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil, the rheology modifier comprises one or more of xanthan gum, carbomer, hydroxyethyl cellulose, hydroxypropyl cellulose and acrylic polymer, the essence comprises essence permitted in cosmetic specification, and the preservative is ethylparaben, sodium benzoate, One or more of benzalkonium chloride, DMDMH (dimethylol dimethyl hydantoin) and diazolidinyl urea.
Example two:
the water-soluble CBD oil-soluble CBD gel comprises the following raw materials in parts by weight: the skin-care lotion comprises, by weight, water, a humectant, an emollient, a solubilizer, a rheology regulator, water-soluble cannabidiol, EDTA-2Na, essence and a preservative, and also comprises hemp seed oil, evening primrose oil, Cannabidiol (CBD) and auxiliary materials, wherein the water comprises 75.2 parts, the humectant comprises 12 parts, the emollient comprises 68 parts, the solubilizer comprises 0.5 part, the rheology regulator comprises 0.5 part, the water-soluble cannabidiol comprises 2 parts, the EDTA-2Na0.1 part, the essence comprises 0.2 part, and the preservative comprises 0.2 part, the hemp seed oil comprises 35%, the evening primrose oil comprises 25%, the Cannabidiol (CBD) comprises 30%, the auxiliary materials comprise 18 parts of glycerol, 34 parts of gelatin, 3 parts of fructose, 2 parts of sorbitol and 30 parts of purified water, the humectant comprises glycerol, propylene glycol, 1, 3-butanediol, glycerol polyether-26, sodium hyaluronate, trehalose, allantoin, betaine and the like, One or more compositions of oat-beta-glucan, emollient including petrolatum, mineral oil, coconut oil, sunflower oil, corn oil and rapeseed oil, soy myristate, octyl caprylate, oleyl oleate, hexyl laurate and isopropyl palmitate, ethoxylated glycerides, PEG-6 caprylic/capric triglycerides, PEG-60 corn oil glycerol mixed ester and PEG-7 olive oleate, one or more compositions of lauryl alcohol, oleyl alcohol, octyl dodecanol and hexyl decanol, dioctyl cyclohexane, solubilizing agent including one or more compositions of PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, rheology modifier including one or more compositions of xanthan gum, carbomer, hydroxyethyl cellulose, hydroxypropyl cellulose, acrylic polymers, perfume including perfumes permitted in cosmetic specifications, the antiseptic is one or more of ethylparaben, sodium benzoate, benzalkonium chloride, DMDMH (dimethylol dimethyl hydantoin) and diazolidinyl urea.
Example three:
the water-soluble CBD oil-soluble CBD gel comprises the following raw materials in parts by weight: the skin-care lotion comprises water, a humectant, an emollient, a solubilizer, a rheology regulator, water-soluble cannabidiol, EDTA-2Na, essence and a preservative, and also comprises hemp seed oil, evening primrose oil, Cannabidiol (CBD) and auxiliary materials, wherein the water is 89.4 parts, the humectant is 18 parts, the emollient is 8 parts, the solubilizer is 1 part, the rheology regulator is 1 part, the water-soluble cannabidiol is 5 parts, EDTA-2Na0.2 part, the essence is 0.5 part, and the preservative is 0.3 part, the hemp seed oil is 45 weight percent, the evening primrose oil is 50 weight percent, the Cannabidiol (CBD) is 40 weight percent, the auxiliary materials comprise 30 parts of glycerol, 50 parts of gelatin, 5 parts of fructose, 5 parts of sorbitol and 50 parts of purified water, the humectant comprises glycerol, propylene glycol, 1, 3-butanediol, glycerol polyether-26, sodium hyaluronate, trehalose, allantoin, betaine and purified water, One or more compositions of oat-beta-glucan, emollient including petrolatum, mineral oil, coconut oil, sunflower oil, corn oil and rapeseed oil, soy myristate, octyl caprylate, oleyl oleate, hexyl laurate and isopropyl palmitate, ethoxylated glycerides, PEG-6 caprylic/capric triglycerides, PEG-60 corn oil glycerol mixed ester and PEG-7 olive oleate, one or more compositions of lauryl alcohol, oleyl alcohol, octyl dodecanol and hexyl decanol, dioctyl cyclohexane, solubilizing agent including one or more compositions of PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, rheology modifier including one or more compositions of xanthan gum, carbomer, hydroxyethyl cellulose, hydroxypropyl cellulose, acrylic polymers, perfume including perfumes permitted in cosmetic specifications, the antiseptic is one or more of ethylparaben, sodium benzoate, benzalkonium chloride, DMDMH (dimethylol dimethyl hydantoin) and diazolidinyl urea.
The invention has the beneficial effects that: the cannabidiol is a natural plant extract, is safe and has no side effect, and is rich in oleic acid, linoleic acid, alpha-linolenic acid, gamma-linoleic acid (GLA) and other human essential unsaturated fatty acids, and gamma-linoleic acid (GLA) can be combined or inserted into cell membranes after entering cell walls, so that the fluidity and other physiological properties of the membranes can be changed, and the growth of thalli can be effectively inhibited, wherein the evening primrose oil mainly comprises linoleic acid and gamma-linolenic acid, and both are polyunsaturated fatty acids, compared with animal oil, the Cannabidiol (CBD) is more beneficial to health and can be used for treating inflammation, premenstrual syndrome and the like, can be used for effectively relieving anxiety, can play a role in metabolism and immunoregulation by regulating and controlling the level of inflammatory factors and controlling the generation of interferon, is healthy and safe, can be taken for a long time, and solves the problem that the inflammation is repeatedly caused because the medicinal ingredients do not fully enter a human body to diminish inflammation in the using process of the existing gynecological gel.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. The oil-soluble CBD gel added with the water-soluble CBD is characterized by comprising the following raw materials in parts by weight: water, humectant, emollient, solubilizer, rheology regulator, water soluble cannabidiol, EDTA-2Na, essence and antiseptic, and optionally oleum Cannabis, oleum Oenotherae Erythrosepalae, Cannabidiol (CBD) and adjuvants.
2. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: 66.2-89.4 parts of water, 8-18 parts of humectant, 2-8 parts of emollient, 0.1-1 part of solubilizer, 0.1-1 part of rheology regulator, 0.3-5 parts of water-soluble cannabidiol, 0.01-0.2 part of EDTA-2 Na0.05-0.5 part of essence and 0.1-0.3 part of preservative.
3. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the hemp seed oil accounts for 30-45 wt%, the evening primrose oil accounts for 20-50 wt%, and the Cannabidiol (CBD) accounts for 10-40 wt%.
4. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the auxiliary materials comprise 5-30 parts of glycerol, 5-50 parts of gelatin, 0.2-5 parts of fructose, 0.2-5 parts of sorbitol and 5-50 parts of purified water.
5. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the humectant comprises one or more of glycerol, propylene glycol, 1, 3-butanediol, glyceryl polyether-26, sodium hyaluronate, trehalose, allantoin, betaine, and oat-beta-glucan.
6. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the emollient comprises one or more of mineral ester, mineral oil, coconut oil, sunflower oil, corn oil and rapeseed oil, soybean myristate, octyl caprylate, oleyl oleate, hexyl laurate and isopropyl palmitate, ethoxylated glyceride, PEG-6 caprylic/capric triglyceride, PEG-60 corn oil and glycerol mixed ester and PEG-7 olive oleate, lauryl alcohol, oleyl alcohol, octyl dodecanol and hexyl decanol, and dioctyl cyclohexane.
7. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the solubilizer comprises one or more of PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil.
8. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the rheology regulator comprises one or more of xanthan gum, carbomer, hydroxyethyl cellulose, hydroxypropyl cellulose and acrylic acid polymer.
9. The addition of a water-soluble CBD oil-soluble CBD gel according to claim 1, wherein: the essence comprises essence permitted in cosmetic specifications, and the preservative is one or more of ethylparaben, sodium benzoate, benzalkonium chloride, DMDMH (dimethylol dimethyl hydantoin) and diazolidinyl urea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010671485.2A CN111686070A (en) | 2020-07-13 | 2020-07-13 | Water-soluble CBD (CBD-based) oil-soluble CBD gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010671485.2A CN111686070A (en) | 2020-07-13 | 2020-07-13 | Water-soluble CBD (CBD-based) oil-soluble CBD gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111686070A true CN111686070A (en) | 2020-09-22 |
Family
ID=72485426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010671485.2A Withdrawn CN111686070A (en) | 2020-07-13 | 2020-07-13 | Water-soluble CBD (CBD-based) oil-soluble CBD gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686070A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843024A (en) * | 2021-01-19 | 2021-05-28 | 优印(上海)信息科技有限公司 | CBD essential oil and preparation method thereof |
| CN113521325A (en) * | 2021-09-09 | 2021-10-22 | 江苏众拾家居科技有限公司 | Steam sterilizing device for furniture surface cloth production |
-
2020
- 2020-07-13 CN CN202010671485.2A patent/CN111686070A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843024A (en) * | 2021-01-19 | 2021-05-28 | 优印(上海)信息科技有限公司 | CBD essential oil and preparation method thereof |
| CN113521325A (en) * | 2021-09-09 | 2021-10-22 | 江苏众拾家居科技有限公司 | Steam sterilizing device for furniture surface cloth production |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1646151B (en) | Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis | |
| RU2452475C2 (en) | Agent for wounds, burns and infectious inflammatory diseases of skin, appendages and mucous membranes | |
| WO2001082861A3 (en) | Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters | |
| CN111686070A (en) | Water-soluble CBD (CBD-based) oil-soluble CBD gel | |
| EP1641459B1 (en) | Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis | |
| CN115501143B (en) | Anti-allergy relieving composition containing saussurea involucrata culture and preparation method thereof | |
| CN104055723A (en) | Natural leave-on sleeping mask | |
| KR102072948B1 (en) | Pharmaceutical Fermented composition for treatment of wound | |
| CN106473961A (en) | A kind of gargarism and preparation method | |
| CN110292539A (en) | It is a kind of repair hormone face peptide composition and its application | |
| CN111419730A (en) | Squalene oxygen injection composition and application thereof | |
| CN1219880A (en) | Acne treatment | |
| EP2815790A1 (en) | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa | |
| CN114376953B (en) | Acne-removing product and preparation process thereof | |
| CN110522686A (en) | A kind of reparation Essence and preparation method thereof | |
| CN108096160B (en) | A cosmetic composition for relieving skin irritation and its preparation method | |
| CN114053175B (en) | Acne-removing product and preparation method thereof | |
| CN101229258B (en) | Antianaphylaxis antiphlogistin | |
| CN107551090A (en) | One kind, which is nourished, repairs gel | |
| CN113559055A (en) | Peony seed oil granulation promoting paste | |
| CN107149641B (en) | Composition for treating burns and scalds | |
| CN111249168A (en) | Composition for preventing mosquito bites and preparation method thereof | |
| CN116869886B (en) | Acne-removing composition, and preparation method and application thereof | |
| KR20150027009A (en) | Use of patchouli extract in the preparation of compositions with an anti-microorganism effect | |
| CN107485644A (en) | A kind of antibacterial anti-inflammatory agent and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200922 |
|
| WW01 | Invention patent application withdrawn after publication |